Dasatinib inhibits adhesion of human and mouse leukocytes in whole serum. (A) Leukocyte-rich human plasma pretreated with the indicated concentrations of dasatinib was incubated with 20 ng/mL of human TNF, 100 ng/mL of human C5a, 1 μg/mL of Pam3CSK4, or 1 μg/mL of ultrapurified LPS (upLPS) on an FCS-coated surface for 30 minutes, followed by determination of cell adhesion. (B) Leukocyte-rich mouse plasma collected 2 hours after oral administration of the indicated doses of dasatinib was stimulated with 50 ng/mL of murine TNF on an FCS-coated surface for 30 minutes, followed by determination of cell adhesion. Bar graphs show mean and SD of representative experiments, and the dose-response curves show mean and SEM of the percent response from 3-9 independent experiments.
